GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Name: GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?
Start: 2021-05-27T00:00:00Z
End: 2021-05-27T00:00:00Z

May 27, 2021

Webinar

LSPN Connect

Finnegan partner Cora Holt will discuss the potential impact the GSK v Teva case will have on both brand and generic drug manufacturers. For more information, or to register, please see LSPN Connect’s website.

Related Insights

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Conference

IAM Live: Navigating the UPC 2026

November 4, 2026

Paris

Conference

2026 ANA Masters of Advertising Law Conference

November 2-4, 2026

Huntington Beach

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Seminar

Future IP UK

October 21, 2026

London

Reception

Congress 2026: Durable Strategy, Enduring Value – Sustainable IP

September 14, 2026

Manchester

Articles

California Brings First CCPA and Delete Act Enforcement Action Against Data Broker

September 4, 2026

European IP Blog

The Decision in G 1/25: A More Relaxed Approach to Description Amendments in Europe?

3 September 2026

Webinar

PTAB Developments and Their Impact on Parallel Litigation: Strategic Considerations

August 26, 2026

Webinar

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Tags

Related Practices

Related Industries

Related Professionals

Related Insights